Model-Informed Approach Supporting Drug Development and Regulatory Evaluation for Rare Diseases

Area of Science:

• Pharmacometrics
• Regulatory Science
• Rare Diseases

Background:

• Rare diseases affect <200,000 people in the US, posing challenges for traditional clinical trials.
• Pediatric populations represent over half of those affected by rare diseases, adding complexity to drug development.
• Maximizing data utilization is crucial for rare disease drug developers and regulators.

Approach:

• Model-informed drug development (MIDD) integrates all available data to assess benefit/risk and inform dosing.
• This review outlines four key MIDD applications: optimizing dose regimens, supporting pediatric extrapolation, informing clinical trial design, and providing confirmatory evidence.
• MIDD leverages population pharmacokinetic (PK) simulations and exposure-response (ER) relationships for efficacy and safety.

Key Points:

• MIDD enables regulatory approval of unstudied dosing regimens in rare diseases without additional clinical data.
• It addresses practical and ethical challenges inherent in rare disease drug development.
• MIDD utilizes comprehensive information, including disease characteristics, drug properties, placebo effects, and nonclinical/clinical exposure-response data.

Conclusions:

• Model-informed approaches are powerful tools applicable throughout the drug development lifecycle for rare diseases.
• MIDD facilitates informed decision-making by quantitatively assessing benefit/risk.
• Integrating diverse data sources through MIDD is essential for advancing rare disease therapeutics.